Analysis of efficacy of peficitinib toward bone structure in rheumatoid arthritis

Iwamoto Naoki0 个研究点目标入组 19 人开始时间: 2022年11月22日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1 The patients who fulfill 2010 ACR/EULAR criteria of rheumatoid arthritis.
•2 The patient aged >18 years when signing his/her informed consent.
•3 The patients who are showing arthritis although the patients have history of DMARDs treatment.
•4 The patients signed infromed consent fof this study.
•5 In case of having tubeculosis history, the patiets under went chest X-ray and a tuberculin reaction or IGRA within one year after consent, and these test need to show negative result about tubeculosis.

•1 Pregnant patients
•2 The patients who is treated with TNF inhibitors, IL-6R inhibitors, abatacept and JAK inhibitors
•3 The patients who is treated with prednisone >10mg
•4 The patients who are taking intraarticular corticosteroid injection into evaluation joints within six months
•5 The patients receiving denosumab
•6 The patients with serious infections such as sepsis
•7 The patients with active tuberculosis
•8 The patients with serious liver dysfunction
•9 The patients with lymphocyte count <500 cells/mm3, absolute neutrophil count<500cells/mm3 or hemoglobin <8 g/dl within three months after consent or most recent blood test before taking peficitinib
•10 In the opinion of the investigator, the patients who is not suitable for this study for other reasons

发起方

Iwamoto Naoki